Open Access Research article

Early effects of oral administration of lafutidine with mosapride compared with lafutidine alone on intragastric pH values

Hiroshi Iida, Masahiko Inamori*, Yuichi Nozaki, Hiroki Endo, Kunihiro Hosono, Tomoyuki Akiyama, Yasunari Sakamoto, Hirokazu Takahashi, Tomoko Koide, Chikako Tokoro, Yasunobu Abe and Atsushi Nakajima

Author Affiliations

Gastroenterology Division, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Japan

For all author emails, please log on.

BMC Gastroenterology 2009, 9:52  doi:10.1186/1471-230X-9-52

Published: 9 July 2009



The ideal medication for treatment of acid related diseases should have a rapid onset of action to promote hemostasis and resolution of symptoms. The aim of our study was to investigate the inhibitory effects on gastric acid secretion after a single oral administrations of lafutidine, is a newly synthesized H2-receptor antagonist, with mosapride 5 mg or lafutidine alone.


Ten Helicobacter pylori negative male subjects participated in this randomized, two-way crossover study. Intragastric pH was monitored continuously for 4 hours after a single oral administration of lafutidine 10 mg or lafutidine 10 mg with mosapride 5 mg (the lafutidine being administrated one hour after the mosapride). Each administration was separated by a 7-day washout period.


The average pH during the 4-hour period after administration of lafutidine 10 mg with mosapride 5 mg was higher than after lafutidine 10 mg alone (median: 5.25 versus 4.58, respectively; p = 0.0318). During the 3–4 hour study period, lafutidine 10 mg with mosapride 5 mg provided a higher pH, compared to lafutidine 10 mg alone (median: 7.28 versus 6.42; p = 0.0208).


In H. pylori negative healthy male subjects, an oral dose of lafutidine 10 mg with mosapride 5 mg more rapidly increased intragastric pH than lafutidine 10 mg alone.